- TNF-alpha Tumor necrosis factor alpha
A central inflammatory cytokine behind many autoimmune diseases; blocked by several drugs.
- IL-6 Interleukin 6
A core inflammatory signal that drives CRP; a consistent predictor of disability and death in older adults.
- SAA Serum amyloid A
An acute-phase protein like CRP that rises sharply with inflammation.
- TNF receptor 1 TNFRSF1A
A shed receptor that reflects long-term TNF activity; predicts kidney decline and mortality.
- TNF receptor 2 TNFRSF1B
Another shed TNF receptor; predicts kidney disease progression, especially in diabetes.
- IL-1 beta IL1B
An early inflammatory trigger; blocking it lowered cardiovascular events in the CANTOS trial.
- IL-1 receptor antagonist IL1RN
The body’s own IL-1 blocker; rises with obesity and predicts type 2 diabetes.
- IL-18 IL18
An inflammasome cytokine; higher levels predict cardiovascular events and rise with metabolic syndrome.
- IL-10 IL10
The main anti-inflammatory cytokine; shows how strongly the body is damping inflammation.
- Soluble IL-6 receptor IL6R
Lets IL-6 signal in cells without their own receptor; gene variants in it change heart risk.
- IL-8 CXCL8
Recruits neutrophils; rises with infection, smoking, and tissue injury.
- CXCL9
An interferon-driven chemokine and a leading marker in inflammatory aging clocks.
- CXCL10 (IP-10) CXCL10
An interferon-driven chemokine that rises with viral infection and autoimmune activity.
- MCP-1 CCL2
Draws monocytes into artery walls and fat; rises with insulin resistance.
- Eotaxin CCL11
Rises with age, and in mouse studies it reduced new neuron growth.
- Interferon gamma IFNG
The main T-cell and NK-cell activation signal; shows type 1 immune activity.
- IL-17A IL17A
Drives psoriasis and other autoimmune inflammation; targeted by biologics.
- IL-13 IL13
A type 2 (allergic) cytokine behind eczema and asthma; targeted by atopic dermatitis drugs.
- IL-4 IL4
The other main type 2 cytokine, active in allergy and eczema; its receptor is blocked by dupilumab.
- suPAR PLAUR
A stable marker of chronic immune activation that predicts kidney disease and mortality.
- YKL-40 CHI3L1
Made by macrophages and liver cells; rises with liver fibrosis, arthritis, and chronic inflammation.
- Soluble CD163 CD163
Shed by activated macrophages; tracks macrophage activation and inflammation in fatty liver.
- Soluble PD-1 PDCD1
Part of the immune checkpoint that restrains T cells.
- PD-L1 CD274
The ligand that PD-1 drugs block; soluble levels rise with some cancers and chronic inflammation.
- LAG-3 LAG3
A T-cell checkpoint and marker of immune exhaustion.
- TIM-3 HAVCR2
A checkpoint on exhausted T cells; rises with chronic infection and inflammation.
- Granzyme B GZMB
The killing enzyme of cytotoxic T cells and NK cells.
- Soluble CD25 IL2RA
A marker of T-cell activation; high in sarcoidosis and some lymphomas.
- C-reactive protein CRP
The most widely used blood marker of inflammation; higher levels predict heart disease.
- Complement C3 C3
A central protein of the complement system, part of the body’s first-line immune defense; a standard lab in autoimmune disease.
- IL-23 IL23A
Keeps IL-17-producing immune cells active; blocked by drugs for psoriasis and inflammatory bowel disease.
- IL-12/IL-23 p40 IL12B
The subunit IL-12 and IL-23 share; the target of ustekinumab in psoriasis and Crohn’s disease.
- IL-5 IL5
Drives eosinophils in allergic asthma; blocked by the asthma drug mepolizumab.
- TSLP
An alarm signal from the airway and skin lining that starts allergic inflammation; blocked by the asthma drug tezepelumab.
- IL-33 IL33
An alarm signal released by damaged tissue; its gene is linked to asthma, and it is a drug target in COPD.